GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » EV-to-FCF

TDSGF (Telo Genomics) EV-to-FCF : -4.08 (As of Mar. 04, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Telo Genomics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Telo Genomics's Enterprise Value is $6.74 Mil. Telo Genomics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.65 Mil. Therefore, Telo Genomics's EV-to-FCF for today is -4.08.

The historical rank and industry rank for Telo Genomics's EV-to-FCF or its related term are showing as below:

TDSGF' s EV-to-FCF Range Over the Past 10 Years
Min: -21.56   Med: 0   Max: 0
Current: -4.35

TDSGF's EV-to-FCF is ranked worse than
100% of 98 companies
in the Medical Diagnostics & Research industry
Industry Median: 25.87 vs TDSGF: -4.35

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-04), Telo Genomics's stock price is $0.0788. Telo Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.028. Therefore, Telo Genomics's PE Ratio (TTM) for today is At Loss.


Telo Genomics EV-to-FCF Historical Data

The historical data trend for Telo Genomics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics EV-to-FCF Chart

Telo Genomics Annual Data
Trend Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.00 -21.70 -10.22 -6.80 -5.28

Telo Genomics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.12 -4.74 -2.85 -5.28 -4.85

Competitive Comparison of Telo Genomics's EV-to-FCF

For the Diagnostics & Research subindustry, Telo Genomics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Telo Genomics's EV-to-FCF falls into.



Telo Genomics EV-to-FCF Calculation

Telo Genomics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6.743/-1.652
=-4.08

Telo Genomics's current Enterprise Value is $6.74 Mil.
Telo Genomics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telo Genomics  (OTCPK:TDSGF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Telo Genomics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0788/-0.028
=At Loss

Telo Genomics's share price for today is $0.0788.
Telo Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.028.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Telo Genomics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Telo Genomics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.